Bayer Intellectual Property GmbH and Bayer Animal Health GmbH v. Ceva Santé Animale SA. and Ceva Santé Animale B.V., District Court The Hague, The Netherlands, 17 September 2019, Case No. ECLI:NL:RBDHA:2019:9764

Reasonable chance that Bayer’s patent will be invalidated by the Technical Board of Appeal or in proceedings on the merits, despite the earlier decision by the Opposition Division. For now, no grounds to grant an injunction. Ceva’s original costs (EUR 306 506) were deemed to be unreasonably high and are lowered to EUR 200 000.

A copy of the decision (in Dutch) can be read here.

[Further headnote follows]